Cheung served as SVP and CFO at SciClone Pharmaceuticals, Inc.
THESSA MULUMALU SERIES
from 2019 to 2022 where he led the efforts to complete a Series C round, and was CFO at KBP Biosciences Inc. Cheung served as EVP and CFO at Apollomics Inc. He is responsible for overseeing the financial management, investor relations, legal and business development strategy of the company. Cheung was appointed CFO of Tessa Therapeutics in April 2022. He graduated with an MBA from Trier University, Germany, and attained a Chinese Language Degree from Sun Yat-Sen University, Guangzhou, China. Thomas speaks German, English and Mandarin. He also spent 12 years with Merck KGaA in various commercial and regional roles in the Asia Pacific region, and as the Head of its German Oncology business unit. Prior to that, Thomas served as Chairman and General Manager for GSK in China, and as General Manager of GSK Taiwan. Prior to Takeda, Thomas held the position of Vice President, Oncology at GlaxoSmithKline (GSK) for its Intercontinental & Emerging Markets business, where he was assigned to develop the business’ strategy for Asia & Emerging Markets, including Access Strategy and Commercial structure design.
.jpg "thessa mulumalu")
He joins Tessa from Takeda Pharmaceuticals, where he served as Senior Vice President, Asia Pacific, leading the transformation of Takeda across 10 markets enhancing the focus on rare and genetic diseases, oncology, and vaccines, based in Singapore. Thomas Willemsen brings over 25 years of extensive international management and leadership experience in the pharmaceutical industry. We are also currently setting up our United States headquarters in New Jersey. Our global headquarters are in Singapore, where we are building our own state-of-the-art commercial manufacturing facility.
Tessa is proud to be innovators in the field of cancer immunotherapy, and remains committed to making a difference in the lives of cancer patients worldwide. Malcolm Brenner, and his team at Baylor College of Medicine. This platform is based on decades-long research and development on unique properties of Virus Specific T-cells (VSTs) by our Scientific Co-Founder, Dr. Tessa is developing a unique and potentially transformational allogeneic CD30-CAR EBVST platform capable of targeting a broad range of cancers. Off-the-shelf allogeneic cell therapy has significant advantages and is the next frontier in cancer treatment. Having received the RMAT and PRIME designation, Tessa is now advancing the therapy to a pivotal trial. Tessa’s approach to target CD30-positive cancers using CAR-T (Chimeric Antigen Receptor) cells has demonstrated excellent safety and efficacy in early clinical trials. CD30 is a well validated lymphoma target with homogenous expression in Classical Hodgkin Lymphoma and multiple subsets of non-Hodgkin Lymphomas. Tessa is leading the way in CD30 targeting using cell therapy. Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer.
0 kommentar(er)
